Hanmi Pharmaceutical Co., Ltd.
http://www.hanmipharm.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Hanmi Pharmaceutical Co., Ltd.
Korea Q1 Roundup: Overseas Sales, COVID Prove Positive In Mixed Results
Among recent highlights, SK Bioscience files for approval of recombinant protein COVID-19 vaccine GBP510, Hanmi Pharmaceutical’s Chinese subsidiary continues to report strong earnings, led by cold drug sales, while Yuhan’s novel peptide drug candidate for degenerative disc disease is set to move into a Phase III trial in the US.
Korea Regulatory Support Group To Speed Drugs, Vaccines For Public Health Crises
The Korean drug ministry has formed a commercialization strategy support group to accelerate the development of drugs and vaccines for public health crises, along with new technologies or concepts, underscoring the significance of successful development of new home-grown options.
Korea’s Home-Grown New Drug Approvals Hit Record High In 2021
South Korea had a milestone year in terms of domestic new drug approvals in 2021, with multiple major pharma firms gaining nods for their in-house developed products, including the country’s first COVID-19 therapeutic, from Celltrion.
US FDA’s 2022 Novel Agent Actions Suggest Acceleration In Use Of Complete Response Letters
COVID does not appear to be a driving factor, and letters are split almost equally between clinical and quality concerns.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Beijing Hanmi Pharmaceutical Co., Ltd.
- Hanmi Holdings Co., Ltd